Investing.com - Financial Markets Worldwide

Ultragenyx director Sanders sells $89k in shares

Published 23/06/2025, 19:06
Ultragenyx director Sanders sells $89k in shares
RARE
2.63%

Director Corazon (Corsee) D. Sanders of Ultragenyx Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:RARE) sold 2,405 shares of common stock on June 20, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The $3.51 billion biotech company, which has seen impressive revenue growth of 33% over the last twelve months, maintains strong liquidity with a current ratio of 2.4.

The shares were sold at a price of $37.39, for a total transaction value of $89922. Following the transaction, Sanders directly owns 15,344 shares of Ultragenyx Pharmaceutical Inc. With the company’s next earnings report due on July 31, InvestingPro subscribers can access comprehensive insider trading analysis and 7 additional ProTips to make informed investment decisions.

In other recent news, Ultragenyx Pharmaceutical Inc. reported its Q1 2025 earnings, showing a 28% increase in total revenue to $139 million compared to the same period last year. Despite the revenue growth, the company posted a net loss of $151 million, or $1.57 per share, narrowly missing the earnings per share forecast of -$1.56. Analyst firm William Blair has given Ultragenyx an Outperform rating with a target price of $65 per share, indicating confidence in the company’s future revenue growth and product pipeline. Ultragenyx has successfully brought four products to market, generating $560 million in revenue in 2024, a 29% increase from the previous year. The company projects continued revenue growth of 14% to 20% for 2025, aiming for a total between $640 million and $670 million. Operating expenses remained high at $282 million, which impacted net income, but the company maintains a strong pipeline with multiple late-stage programs. Ultragenyx’s strategic commercialization efforts are expected to drive further revenue growth, with a focus on expanding its market presence in Latin America and other regions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.